Sign inJoin waitlistJoin the waitlist

Aung Naing

Professor · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

H. Lee Moffitt Cancer Center and Research Institute
2006–2008
City of Hope Cancer Center
2005–2006
H. Lee Moffitt Cancer Center and Research Institute
2002–2005
Internal Medicine
SUNY Upstate Medical University
1999–2002
Doctor of Medicine
1993–1997

Research

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 2,915 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Journal of Clinical Oncology · 2021 · 1,863 citations
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
Cell · 2020 · 612 citations

David Hong
218 papers
Siqing Fu
179 papers
Apostolia Tsimberidou
155 papers
Sarina Piha-Paul
153 papers
Razelle Kurzrock
144 papers
FJ
Filip Janku
123 papers
Funda Meric-Bernstam
109 papers
JW
Jennifer Wheler
108 papers
GF
Gerald Falchook
100 papers
Vivek Subbiah
95 papers · 1 as a fellow
DK
Daniel Karp
73 papers
RZ
Ralph Zinner
41 papers

Grants

Integrating Patient-Reported Outcomes and T-Cell Receptor Sequencing to Predict Immune-Related Adverse Events
National Cancer Institute · R01
Contact PI · $1.9M · University of Tx Md Anderson Can Ctr
2024–2028
Phase I Study of IMC-A12 in Combination with Temsirolimus
National Cancer Institute · R21
Contact PI · $664.7K · University of Tx Md Anderson Can Ctr
2009–2012

Clinical trials

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2026–2032
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2030
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
Principal investigator · Recruiting · Phase 1
Zhuhai Fapon Biopharma Co., Ltd.
2025–2028
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2025–2030